[go: up one dir, main page]

EP1397119A2 - Utilisation de polystyrene sulfonate de sodium pour raffermir la peau - Google Patents

Utilisation de polystyrene sulfonate de sodium pour raffermir la peau

Info

Publication number
EP1397119A2
EP1397119A2 EP02738131A EP02738131A EP1397119A2 EP 1397119 A2 EP1397119 A2 EP 1397119A2 EP 02738131 A EP02738131 A EP 02738131A EP 02738131 A EP02738131 A EP 02738131A EP 1397119 A2 EP1397119 A2 EP 1397119A2
Authority
EP
European Patent Office
Prior art keywords
acid
cosmetic
skin
derivatives
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02738131A
Other languages
German (de)
English (en)
Inventor
Rainer Kröpke
Jens Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1397119A2 publication Critical patent/EP1397119A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0212—Face masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8117—Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Definitions

  • the present invention relates to cosmetic or dermatological dermatological preparations containing active ingredients for protecting and protecting the skin, in particular sensitive skin, as well as particularly in the foreground for skin aged or aging due to intrinsic and / or extrinsic factors, and the use of such active ingredients and Combinations of such active ingredients in the field of cosmetic and dermatological skin care.
  • Cosmetic skin care is primarily understood to mean that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, natural fats, electrolytes) is strengthened or restored.
  • environmental influences e.g. dirt, chemicals, microorganisms
  • loss of the body's own substances e.g. water, natural fats, electrolytes
  • the aim of skin care is also to compensate for the loss of fat and water in the skin caused by daily washing. This is especially important when the natural regeneration ability is insufficient.
  • skin care products are intended to protect against environmental influences, especially sun and wind, and to delay skin aging.
  • Chronological skin aging is caused, for example, by endogenous, genetically determined factors.
  • the following structural damage and functional disorders occur in the epidermis and dermis due to aging, which can also fall under the term "senile xerosis”: a) dryness, roughness and formation of dry wrinkles, b) itching and c) reduced regreasing due to sebum glands (eg after washing).
  • Exogenous factors such as UV light and chemical pollutants, can be cumulative and e.g. accelerate or complement the endogenous aging processes.
  • exogenous factors e.g. the following structural damage and functional disorders in the skin that go beyond the extent and quality of the damage with chronological aging:
  • the present invention relates in particular to products for the care of skin aged naturally, and to the phenomena listed under a), e) and g).
  • Products for the care of sagging, especially aged skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
  • Retinoids vitamin A acid and / or its derivatives
  • their effect on structural damage is limited in scope.
  • the use of products containing vitamin A acid often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.
  • the sagging skin is also associated with an overweight and / or the associated so-called cellulite.
  • Cellulite - one widespread phenomenon - occupies a central position.
  • the visible picture of cellulite is based on an increase in fat deposits in the subcutis (subcutaneous fatty tissue), weak connective tissue and a decrease in the flow conditions in the blood and lymph channels.
  • the cause is thus a partially plant-related weakening of the connective tissue with the simultaneous appearance of enlarged fat cell chambers due to overweight, unbalanced nutrition, lack of exercise.
  • the development of cellulite can also be attributed to an increased permeability of the hair vessel walls, which allows water to penetrate into the connective tissue.
  • the object of the present invention was therefore to find ways which avoid the disadvantages of the prior art.
  • Sodium polystyrene sulfonate is sold, for example, under the trade name Flexan®. It is a high molecular weight polystyrene sulfonate with an anionic character and is available as a 30% aqueous solution; it corresponds to the following formula; its CTFA name is "Sodium Polystyrene Sulfonate". Because of its ionic character, it is highly conductive and prevents the hair from being charged in hair cosmetic preparations in low concentrations.
  • sodium polystyrene sulfonate is particularly advantageous for the production of cosmetic or dermatological preparations for cosmetic and / or dermatological treatment and / or prophylaxis of cellulite.
  • the amount of sodium polystyrene sulfonate in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight of the preparation.
  • preparations containing the active compound combinations according to the invention, customary antioxidants can be used.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan, proline) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-camosine, D-carnosine, L-carnosine and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g.
  • amino acids eg glycine, histidine, tyrosine, tryptophan, proline
  • imidazoles eg urocanic acid
  • peptides such as D, L-camosine, D-carnosine, L-carnosine and its derivatives (e.g. anserine)
  • carotenoids e.g.
  • thiols e.g. thioredoxin , Glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl , Cholesteryl and glyceryl esters
  • salts dilauryl thiodipropionate, distearyl thiodipropionate, thiodi- propionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthionine sulfoximines in very low tolerable dosages (e.g. pmol to ⁇ mol / kg), also (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • citric acid lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and its derivatives
  • unsaturated fatty acids and their derivatives e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (e.g.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is carried out in the usual way, namely in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • Emulsions according to the invention in the sense of the present invention are advantageous and contain, for example, fats, oils, waxes and / or other fat bodies, as well as water and one or more re emulsifiers, as are usually used for such a type of formulation.
  • Medical topical compositions in the sense of the present invention generally contain one or more medicaments in an effective concentration.
  • medicaments in an effective concentration.
  • cosmetic or topical dermatological compositions within the meaning of the present invention, depending on their structure, can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to use the compositions according to the invention as a basis for pharmaceuticals Use wording. However, it is also advantageous in the sense of the present inventions to create such cosmetic and dermatological preparations, the main purpose of which is not protection against sunlight, but which nevertheless contain UV protection substances. For example, UV-A or UV-B filter substances are usually incorporated into day creams.
  • Preparations according to the invention can advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the preparations.
  • the UVB filters can be oil-soluble or water-soluble.
  • oil-soluble substances e.g. to call:
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester;
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;
  • 2-phenylbenzimidazole-5-sulfonic acid and its salts e.g. Sodium, potassium or triethanolammonium salts
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxy-benzophenone-5-sulfonic acid and their salts
  • Sulfonic acid derivatives of 3-benzylidene camphor such as 4- (2-oxo-3-bomyli- denmethyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidenemethyl) sulfonic acid and their salts.
  • UVB filters which can be used according to the invention, is of course not intended to be limiting.
  • the invention also relates to the combination of a UVA filter according to the invention with a UVB filter or a cosmetic or dermatological preparation according to the invention which also contains a UVB filter.
  • UVA filters in the preparations according to the invention, which are usually contained in cosmetic and / or dermatological preparations.
  • Such filter substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- ( 4'-isopropylphenyl) propane-1,3-dione.
  • Preparations containing these combinations are also the subject of the invention.
  • the same amounts of UVA filter substances that were mentioned for UVB filter substances can be used.
  • Cosmetic and / or dermatological preparations in the sense of the present invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. The amounts given for the above combinations can be used.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic active ingredients, auxiliaries and / or additives as are usually used in such preparations, for example antioxidants, preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments, the coloring effect have thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances zen, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic active ingredients for example antioxidants, preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments, the coloring effect have thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances zen, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, poly
  • the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products ,
  • Water can also be a component of alcoholic solvents.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions for the purposes of the present invention is advantageously selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethyl-2-ethylhexyl palmitate Hexyl decyl stearate, 2-oc- tyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate as well as synthetic, semi-synthetic and natural mixtures of such esters, for example jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also contain cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Cyclomethicone octamethylcyclotetrasiloxane
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products , further alcohols of low C number, for example Ethanol, isopropanol, 1,2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, e.g.
  • Hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbopoles, for example carbopoles of types 980, 981, 1382, 2984, 5984, in each case individually or in combination.
  • liquid oils for example paraffin oils, castor oil, isopropyl myristate
  • semi-solid components for example petroleum jelly, lanolin
  • solid components for example beeswax, ceresin and microcrystallines
  • Waxes or ozokerite for example beeswax, ceresin and microcrystallines
  • high-melting waxes e.g. carnauba wax, candelilla wax
  • Suitable blowing agents for cosmetic and / or dermatological O / W emulsions sprayable from aerosol containers for the purposes of the present invention are the customary known volatile, liquefied blowing agents, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another , Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • Compressed air can also be used advantageously.
  • non-toxic propellant gases per se which would in principle be suitable for the implementation of the present invention in the form of aerosol preparations, but which should nevertheless be dispensed with because of their harmful effects on the environment or other associated circumstances, in particular fluorocarbons and chlorofluorocarbons ( CFC).
  • Cosmetic preparations within the meaning of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents conventionally used for this purpose, preferably water, or organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, Hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, eg. B. aluminum silicates such as bentonite, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • the thickener is contained in the gel, for example, in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • Example 12 Hydrodispersion / Gel Cream

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Image Processing (AREA)

Abstract

L'invention concerne l'utilisation de polystyrène sulfonate de sodium afin de produire des préparations cosmétiques ou dermatologiques destinées à raffermir la peau et/ou à renforcer sa résistance.
EP02738131A 2001-06-02 2002-05-31 Utilisation de polystyrene sulfonate de sodium pour raffermir la peau Withdrawn EP1397119A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10127087A DE10127087A1 (de) 2001-06-02 2001-06-02 Verwendung von Natriumpolystyrolsulfonat zur Hautstraffung
DE10127087 2001-06-02
PCT/EP2002/005950 WO2002098386A2 (fr) 2001-06-02 2002-05-31 Utilisation de polystyrene sulfonate de sodium pour raffermir la peau

Publications (1)

Publication Number Publication Date
EP1397119A2 true EP1397119A2 (fr) 2004-03-17

Family

ID=7687139

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02738131A Withdrawn EP1397119A2 (fr) 2001-06-02 2002-05-31 Utilisation de polystyrene sulfonate de sodium pour raffermir la peau

Country Status (5)

Country Link
US (1) US20040141936A1 (fr)
EP (1) EP1397119A2 (fr)
DE (1) DE10127087A1 (fr)
ES (1) ES2616867T3 (fr)
WO (1) WO2002098386A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004018723A1 (de) * 2004-04-17 2005-11-03 Wella Ag Itaconsäuremonoester/Acrylat Copolymer und Polystyrolsulfonat enthaltende Haarbehandlungsmittel
US8795730B2 (en) * 2006-01-31 2014-08-05 David John Vachon Compositions and methods for promoting the healing of tissue of multicellular organisms
DE102011081434A1 (de) * 2011-08-23 2013-02-28 Henkel Ag & Co. Kgaa Hautstraffende kosmetische Zusammensetzungen mit angenehmer Produkthaptik
WO2013093332A2 (fr) 2011-12-20 2013-06-27 L'oreal Composition cosmétique comprenant un tensioactif anionique, un alcool gras solide et un ester gras solide, et procédé de traitement cosmétique
JP2014062088A (ja) * 2012-08-30 2014-04-10 Kao Corp 毛髪化粧料
US9672952B2 (en) 2013-08-14 2017-06-06 Industrial Technology Research Institute Polymer and conductive composition
CN110384645B (zh) * 2019-09-06 2022-05-17 广州留今科学研究有限公司 一种抗皱皮肤调理剂、美颈霜及制备方法
WO2022094595A1 (fr) * 2020-10-30 2022-05-05 Mary Kay Inc. Crème oculaire à effet instantané
US12115173B2 (en) 2021-02-09 2024-10-15 Elba Laboratories Compositions of hydroxy acids with salicylic acid and uses therefore

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83350A1 (fr) * 1981-05-08 1983-03-24 Oreal Composition destinee au traitement des fibres keratiniques a base de polymere cationique et de polymere anionique a groupements vinylsulfoniques et procede de traitement la mettant en oeuvre
LU84210A1 (fr) * 1982-06-17 1984-03-07 Oreal Composition a base de polymeres cationiques,de polymeres anioniques et de cires destinee a etre utilisee en cosmetique
US5063057A (en) * 1990-09-26 1991-11-05 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic capsules
DE69010889T2 (de) * 1990-04-27 1994-11-24 Unilever Nv Kosmetische Kapseln.
US5667772A (en) * 1992-10-29 1997-09-16 Lancaster Group Ag Preparation containing a fluorocarbon emulsion and usable as cosmetics or dermatics
US5747022A (en) * 1993-07-30 1998-05-05 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic mask
DE19842744B4 (de) * 1998-09-18 2006-12-21 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl und deren Verwendung
FR2791258B1 (fr) * 1999-03-22 2001-08-24 Oreal Composition amincissante
DE19923672A1 (de) * 1999-05-22 2000-11-23 Beiersdorf Ag Kosmetische oder dermatologische Lichtschutzzubereitungen mit einem Gehalt an Dioctylbutamidotriazon und einem oder mehreren Filmbildnern und einem oder mehreren Polymeren
DE10019210A1 (de) * 2000-04-18 2001-10-25 Beiersdorf Ag Zubereitungen vom Emulsionstyp W/O mit niedrigviskosen gut spreitenden Lipidkomponenten
DE10032118B9 (de) * 2000-07-01 2006-12-07 Wella Ag Antithixotropes kosmetisches Mittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO02098386A3 *

Also Published As

Publication number Publication date
US20040141936A1 (en) 2004-07-22
ES2616867T3 (es) 2017-06-14
DE10127087A1 (de) 2002-12-05
WO2002098386A3 (fr) 2003-04-10
WO2002098386A2 (fr) 2002-12-12

Similar Documents

Publication Publication Date Title
DE4444238A1 (de) Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
WO2002002075A1 (fr) Utilisation de creatine et/ou de derives de creatine dans des preparations cosmetiques ou dermatologues
WO2001003657A1 (fr) Agent pour usage topique a action protectrice et regeneratrice, comprenant de l'idebenone
WO2003011242A1 (fr) Preparations cosmetiques ou dermatologiques a combinaison de creatinine et/ou de derives de creatinine avec la creatinine et ou ses derives
EP1324745A1 (fr) Preparations cosmetiques et dermatologiques contenant de l'aminoguanidine
EP0965331A2 (fr) Preparation d'emulsion du type W/O à haute teneur en eau, contenant aussi un ou plusieurs copolyalcool de alkyl methicone et/ou copolyalcool de alkyl dimethicone
DE10128910A1 (de) Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
EP1049453A2 (fr) Preparations cosmetiques ou pharmaceutiques a effet collant amoindri, contenant des esters glyceriques d'acides alfa-hydroxycarboxyliques et d'acides gras satures
EP1084701A1 (fr) Emulsion H/E contenant un ou plusieurs bioquinones et un teneur de glycerine élevée
DE19720339A1 (de) Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung
DE102004032837A1 (de) Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
EP1397119A2 (fr) Utilisation de polystyrene sulfonate de sodium pour raffermir la peau
WO2003011241A1 (fr) Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques
DE10032165A1 (de) Verwendung von physiologisch verträglichen Sulfinsäuren als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen
EP1529520A1 (fr) Utilisation de licochalcone A ou d'un extrait de Radix Glycyrrhizae inflatae contenant du licochalcone A contre la hyperpigmentation postinflammatoire
EP0945127A2 (fr) Utilisation de l'acylcarnitine
DE29924371U1 (de) O/W-Emulsionen mit einem Gehalt an einem oder mehreren Biochinonen und einem erhöhten Gehalt an Glycerin
WO2002076409A2 (fr) Preparations cosmetiques et dermatologiques contenant des isoflavones et utilisation d'isoflavones pour produire des preparations cosmetiques et dermatologiques destinees a reduire le taux de sebum de la peau
DE19739349A1 (de) Verwendung von Troxerutin als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen
WO2002076410A2 (fr) Preparations cosmetiques et dermatologiques renfermant un extrait de houblon ou de houblon-malt et utilisation d'un extrait de houblon ou de houblon-malt dans la production de preparations cosmetiques et dermatologiques servant a reduire la secretion de sebum cutane
DE19615576A1 (de) Verfahren zur Herstellung von Mono- und/oder Diglucosiden des Glabridins und deren Verwendung als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
DE10048261A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Pyridoxamin zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
WO2004089326A1 (fr) Preparations cosmetiques ou dermatologiques contenant une combinaison de creatinine, de creatine et de quinones biologiques
DE19739044A1 (de) Verwendung von Dihydrorobinetin als Antioxidans oder Radikalfänger in kosmetischen oder dermatologischen Zubereitungen
DE10158076A1 (de) Kosmetische und/oder dermatologische Zubereitungen mit einem Gehalt an Aryl-Ureido-Verbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040102

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20061124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070605